Table 1.
Patient and treatment characteristics.
| Imatinib n = 80 (%) | Sunitinib n = 32 (%) | |
|---|---|---|
| Sex | ||
| Male | 51 (64) | 10 (31) |
| Female | 29 (36) | 22 (69) |
|
| ||
| Age, years | ||
| Median (years) | 63 | 61 |
| Range | 30–87 | 40–85 |
|
| ||
| Performance status | ||
| 0 | 54 (68) | 24 (75) |
| 1 | 18 (22) | 6 (19) |
| 2 | 7 (9) | 1 (3) |
| 3 | 1 (1) | 1 (3) |
|
| ||
| Concomitant disease | ||
| No | 45 (56) | 21 (66) |
| Yes | 35 (44) | 11 (34) |
|
| ||
| Prior malignancy | ||
| No | 72 (90) | 28 (88) |
| Yes | 8 (10) | 4 (12) |
|
| ||
| Primary treatment | ||
| Surgery | 49 (61) | 22 (69) |
| No prior surgery | 31 (39) | 10 (31) |
|
| ||
| Start dose of imatinib/sunitinib | ||
| 800 mg/50 mg | 10 (13) | 10 (31) |
| 400 mg/37,5 mg | 69 (86) | 19 (60) |
| 200 mg/25 mg | 1 (1) | 3 (9) |
|
| ||
| Permanent reduction of start dose | ||
| No | 61 (76) | 25 (78) |
| Yes | 19 (24) | 7 (22) |
|
| ||
| Reason for reduction of start dose | ||
| Haematological | 2 (11) | |
| Musculoskeletal | 2 (11) | 3 (43) |
| Multisystem | 1 (5) | |
| Dermatological | 7 (37) | 3 (43) |
| Gastrointestinal | 6 (31) | |
| Other | 1 (5) | 1 (14) |
|
| ||
| Response(a) | ||
| CR | 3 (4) | |
| PR | 47 (59) | 13 (41) |
| SD | 16 (20) | 13 (41) |
| PD | 13 (16) | 3 (9) |
| Death before evaluation | 1 (1) | 3 (9) |
|
| ||
| Progression(b) | ||
| No | 26 (33) | 8 (25) |
| Yes | 52 (65) | 19 (59) |
| Not evaluable | 2 (2) | 5 (16) |
|
| ||
| Local treatment | ||
| No | 40 (77) | 17 (89) |
| Yes | 12 (23) | 2 (11) |
(a)Best response at any time during treatment. CR: complete response, PR: partial response, SD: stable disease, PD: progression of disease.
(b)Progression at the time of evaluation.